BiVictriX Therapeutics plc (AIM:BVX)
London · Delayed Price · Currency is GBP · Price in GBX 10.00
+1.50 (17.65%)
Inactive · Last trade price on Sep 10, 2024
17.65% (1Y)
| Market Cap | 8.25M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.67M |
| Shares Out | 82.53M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,774,830 |
| Average Volume | 1,101,011 |
| Open | n/a |
| Previous Close | 8.50 |
| Day's Range | 10.00 - 10.00 |
| 52-Week Range | 10.00 - 14.00 |
| Beta | n/a |
| RSI | 59.32 |
| Earnings Date | Sep 17, 2024 |
About BiVictriX Therapeutics
BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia. The company was formerly known as BiVictriX Plc and changed its name to BiVictriX Therapeutics Plc in August 2021. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom. [Read more]
Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 17
Stock Exchange London Stock Exchange AIM
Ticker Symbol BVX
Financial Performance
Financial StatementsNews
Small Cap Stocks: Global Petroleum, Oncimmune
Global Petroleum, Oncimmune, Sunda Energy, Celadon Pharmaceuticals and Bivictrix Therapeutics are the biggest Small Cap stock movers
1 year ago - The Armchair Trader